Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer

被引:17
作者
Barton, Michelle Craig
Akli, Said
Keyomarsi, Khandan
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA
[3] Univ Texas, Hlth Sci Ctr, Grad Program Genes & Dev, Grad Sch Biomed Sci, Houston, TX USA
[4] Univ Texas, Hlth Sci Ctr, Canc Biol Program, Grad Sch Biomed Sci, Houston, TX USA
关键词
D O I
10.1002/jcp.20818
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In this review, we focus on pathways intersecting through p53 and cyclin E, highlighting how oncogenic effects of cyclin E deregulation, especially overexpression of shortened or low molecular weight (LMW) forms of cycl in E protein, are amplified by loss of regulatory control through p53 to promote tumor development. Expression of cyclin E protein promotes progression into S-phase, an activity opposed by p53-regulated activation of checkpoint controls or apoptosis. Loss of p53 function is an escape hatch by which tumor cells, initiated by a number of means including cyclin E deregulation, can avoid cell cycle arrest or cell death and progress through further stages of unchecked deregylation and growth. To determine how this escape hatch is opened and, ultimately, how to close it, we must understand the networks of normal signaling and processing in a cell and where they intersect.
引用
收藏
页码:686 / 694
页数:9
相关论文
共 126 条
[1]   Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p2l, p27, and antiestrogens in breast cancer [J].
Akli, S ;
Zheng, PJ ;
Multani, AS ;
Wingate, HF ;
Pathak, S ;
Zhang, N ;
Tucker, SL ;
Chang, S ;
Keyomarsi, K .
CANCER RESEARCH, 2004, 64 (09) :3198-3208
[2]  
Akli S, 2003, CANCER BIOL THER, V2, pS38
[3]   p53-Mdm2 - the affair that never ends [J].
Alarcon-Vargas, D ;
Ronai, Z .
CARCINOGENESIS, 2002, 23 (04) :541-547
[4]   A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells [J].
Arva, NC ;
Gopen, TR ;
Talbott, KE ;
Campbell, LE ;
Chicas, A ;
White, DE ;
Bond, GL ;
Levine, AJ ;
Bargonetti, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) :26776-26787
[5]   Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases [J].
Barlev, NA ;
Liu, L ;
Chehab, NH ;
Mansfield, K ;
Harris, KG ;
Halazonetis, TD ;
Berger, SL .
MOLECULAR CELL, 2001, 8 (06) :1243-1254
[6]   p53 in signaling checkpoint arrest or apoptosis [J].
Bates, S ;
Vousden, KH .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (01) :12-18
[7]   Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points [J].
Bible, KC ;
Lensing, JL ;
Nelson, SA ;
Lee, YK ;
Reid, JM ;
Ames, MM ;
Isham, CR ;
Piens, J ;
Rubin, SL ;
Rubin, J ;
Kaufmann, SH ;
Atherton, PJ ;
Sloan, JA ;
Daiss, MK ;
Adjei, AA ;
Erlichman, C .
CLINICAL CANCER RESEARCH, 2005, 11 (16) :5935-5941
[8]   Post-translational modification of p53 in tumorigenesis [J].
Bode, AM ;
Dong, ZG .
NATURE REVIEWS CANCER, 2004, 4 (10) :793-805
[9]   Association of breast cancer outcome with status of p53 and MDM2 SNP309 [J].
Boersma, Brenda J. ;
Howe, Tiffany M. ;
Goodman, Julie E. ;
Yfantis, Harry G. ;
Lee, Dong H. ;
Chanock, Stephen J. ;
Ambs, Stefan .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (13) :911-919
[10]   A single nucleotide polymorphism in the MDM2 gene:: From a molecular and cellular explanation to clinical effect [J].
Bond, GL ;
Hu, WW ;
Levine, A .
CANCER RESEARCH, 2005, 65 (13) :5481-5484